HC Wainwright Has Bearish Outlook for XENE FY2026 Earnings

Key Points

• HC Wainwright lowered its FY2026 EPS estimate for Xenon Pharmaceuticals to a loss of $4.53 per share from $4.48, while maintaining a Buy rating.
• Xenon reported a quarterly loss of $1.11 per share, slightly better than analysts’ $1.13-per-share loss estimate.
• Analyst sentiment remains broadly positive: MarketBeat reports a “Moderate Buy” consensus rating and an average price target of $71.31.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Research analysts at HC Wainwright decreased their FY2026 EPS estimates for shares of Xenon Pharmaceuticals in a research note issued on Tuesday, November 10th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will post earnings per share of ($4.53) for the year, down from their previous forecast of ($4.48). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($4.66) per share. HC Wainwright also issued estimates for Xenon Pharmaceuticals' Q4 2026 earnings at ($1.14) EPS, Q2 2027 earnings at ($1.22) EPS, Q4 2027 earnings at ($1.25) EPS, FY2027 earnings at ($4.90) EPS, FY2028 earnings at ($4.07) EPS, FY2029 earnings at ($2.25) EPS and FY2030 earnings at ($0.44) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its earnings results on Monday, November 9th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.13) by $0.02.

Several other equities analysts have also weighed in on the stock. Guggenheim started coverage on shares of Xenon Pharmaceuticals in a report on Tuesday, October 6th. They set a "buy" rating and a $73.00 price objective on the stock. Wall Street Zen downgraded Xenon Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research note on Sunday, October 11th. Wedbush reduced their target price on Xenon Pharmaceuticals from $71.00 to $55.00 and set an "outperform" rating for the company in a research note on Friday, September 18th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $90.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday, September 28th. Finally, Robert W. Baird dropped their price target on Xenon Pharmaceuticals from $97.00 to $90.00 and set an "outperform" rating on the stock in a research note on Friday, September 18th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Xenon Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $71.31.

Xenon Pharmaceuticals Trading Up 1.7%

NASDAQ:XENE opened at $42.10 on Thursday. The stock has a market capitalization of $4.07 billion, a price-to-earnings ratio of -8.96 and a beta of 0.11. The firm has a fifty day simple moving average of $41.91 and a two-hundred day simple moving average of $52.14. Xenon Pharmaceuticals has a 12 month low of $33.38 and a 12 month high of $72.66.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in XENE. Cibc World Market Inc. increased its holdings in Xenon Pharmaceuticals by 3.4% during the 3rd quarter. Cibc World Market Inc. now owns 20,632 shares of the biopharmaceutical company's stock worth $767,000 after purchasing an additional 672 shares in the last quarter. Diversified Trust Co boosted its holdings in shares of Xenon Pharmaceuticals by 4.9% in the 3rd quarter. Diversified Trust Co now owns 41,160 shares of the biopharmaceutical company's stock worth $1,531,000 after buying an additional 1,938 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in Xenon Pharmaceuticals by 29.3% during the third quarter. Russell Investments Group Ltd. now owns 198,100 shares of the biopharmaceutical company's stock worth $7,373,000 after buying an additional 44,873 shares during the last quarter. Eurizon Capital SGR S.p.A. raised its position in Xenon Pharmaceuticals by 34.5% in the third quarter. Eurizon Capital SGR S.p.A. now owns 3,802 shares of the biopharmaceutical company's stock worth $142,000 after acquiring an additional 976 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its position in Xenon Pharmaceuticals by 5.5% in the third quarter. Allspring Global Investments Holdings LLC now owns 247,330 shares of the biopharmaceutical company's stock worth $9,629,000 after acquiring an additional 12,918 shares during the period. 95.45% of the stock is owned by institutional investors.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, CFO Thomas Patrick Kelly acquired 15,000 shares of the company's stock in a transaction on Wednesday, September 30th. The shares were purchased at an average cost of $37.32 per share, with a total value of $559,800.00. Following the completion of the purchase, the chief financial officer owned 15,000 shares of the company's stock, valued at approximately $559,800. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Christopher Kenney sold 7,068 shares of the firm's stock in a transaction on Friday, August 28th. The shares were sold at an average price of $60.25, for a total transaction of $425,847.00. Following the completion of the transaction, the insider directly owned 2 shares in the company, valued at $120.50. This trade represents a 99.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.91% of the stock is currently owned by company insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for neurological disorders. The company's research emphasizes ion channels, proteins that help regulate the electrical activity of nerve cells. Its lead program is azetukalner, formerly known as XEN1101, an oral Kv7 potassium-channel opener being developed for seizure disorders, including focal epilepsy. Xenon is also advancing other drug candidates aimed at neurological conditions. Founded in 1996, Xenon is headquartered in Burnaby, British Columbia, and conducts drug development activities in North America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.